Poster Session III


Background: Alpha7 nicotinic acetylcholine receptors (nAchRs) play a vital role in cognition and alpha7 nAchR agonists represent a novel drug class with therapeutic potential to restore cognitive abnormalities associated with Alzheimer’s disease, schizophrenia and other CNS disorders. MEM 3454 is a novel alpha7 nAchR partial agonist with 5HT3 receptor… (More)
DOI: 10.1038/sj.npp.1301268


Cite this paper

@article{Callahan2006PosterSI, title={Poster Session III}, author={Patrick M. Callahan and Shaojie Wang and Walter Xie and Sofya Dragan and Shuangdan Sun}, journal={Neuropsychopharmacology}, year={2006}, volume={31}, pages={S198-S263} }